News & Updates
Filter by Specialty:
Osimertinib plus chemo bumps up PFS in advanced EGFR-mutated NSCLC
In the first-line treatment of patients with advanced nonsmall cell lung cancer (NSCLC) harbouring EGFR mutation, the combination of osimertinib plus pemetrexed and platinum-based chemotherapy outperformed osimertinib alone in terms of extending progression-free survival (PFS), according to the interim results of the phase III FLAURA2 trial presented at WCLC 2023.
Osimertinib plus chemo bumps up PFS in advanced EGFR-mutated NSCLC
12 Oct 2023
Do antiemetic drugs prevent chemotherapy-induced nausea, vomiting in cancer patients?
Cancer patients who are being treated with chemotherapy are susceptible to chemotherapy-induced nausea and vomiting (CINV), and they continue to experience these side effects despite being administered with antiemetics, a study has shown.
Do antiemetic drugs prevent chemotherapy-induced nausea, vomiting in cancer patients?
11 Oct 2023
Ginseng may protect breast cancer patients against doxorubicin-induced cardiac toxicity
Supplementation with ginseng appears to provide protective benefits against early cancer therapeutics-related cardiac dysfunction caused by doxorubicin and may help prevent early decline in left ventricular ejection fraction in patients with breast cancer, suggests a study.
Ginseng may protect breast cancer patients against doxorubicin-induced cardiac toxicity
10 Oct 2023
ALA-PDT on par with minocycline for moderate-to-severe rosacea
Patients with moderate-to-severe rosacea may benefit from treatment with 5-aminolevulinic acid photodynamic therapy (ALA-PDT), which has shown its efficacy and noninferiority to minocycline in a recent study.